Market Overview

ImmunoGen To Focus Operations On Mivetuximab Soravtansine Development


ImmunoGen (NASDAQ: IMGN) focuses on antibody-drug conjugates for the treatment of cancer and the company said Thursday it will prioritize continued development of “Mivetuximab Soravtansine” targeting solid tumors

Mirvetuximab Soravtansine is a potential new treatment for patients with folate receptor alpha (FRα)-positive cancer.

ImmunoGen shares traded lwoer by 1.5% to $1.90 at time of publication.

Related Links:

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA

Posted-In: News Health Care General


Related Articles (IMGN)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

10 Biggest Price Target Changes For Thursday

Credit Suisse Initiates Tesla At Underperform, Says Company Compares 'Most Appropriately' To Volkswagen